AI-generated suggestion. Not a real company. Not a forecast.
Acme Confirmed cases of RR-/MDR-TB Co. (open quest, not a real company)
This placeholder is not counted as supply. It has no revenue, funding, or valuation.
Founder starter pack
A company whose job is Confirmed cases of RR-/MDR-TB, and whose progress report is the sourced figure of 173,308 cases in 2024.
Customer: The people counted in the headline metric, and the payer that already spends money when the condition gets worse.
First product: one measured pilot in one health system. Pick the headline metric, pick one site, and see if that sourced number moves.
Metrics to move
- Confirmed cases of RR-/MDR-TB: 173,308 cases (2024) Source
Key papers
Most-cited OpenAlex articles returned for a short title search on this problem. A neighboring topic can still appear. This is not a curated reading list.
- Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis · 2010 · 1,050 citations in OpenAlex
- An Outbreak of Multidrug-Resistant Tuberculosis among Hospitalized Patients with the Acquired Immunodeficiency Syndrome · 1992 · 843 citations in OpenAlex
- The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis · 2009 · 841 citations in OpenAlex
- Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline · 2014 · 758 citations in OpenAlex
- Delamanid for Multidrug-Resistant Pulmonary Tuberculosis · 2012 · 758 citations in OpenAlex
- Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study · 2019 · 754 citations in OpenAlex
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis · 2010 · 659 citations in OpenAlex
- Global Incidence of Multidrug‐Resistant Tuberculosis · 2006 · 527 citations in OpenAlex
Datasets
Funders and grant programs
- NIH RePORTER 1 projects matched this search in FY2026. A match is not an open call.
- Wellcome Wellcome lists open research funding. Check the current scheme before applying.
Comparable companies
No comparable company was sourced.